Joffe Hylton V, Goldhaber Samuel Z
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Vasc Med. 2002 May;7(2):93-102. doi: 10.1191/1358863x02vm426ra.
Inherited abnormalities of coagulation are increasingly recognized in patients with venous thromboembolism. Common causes of hypercoagulability, also known as thrombophilia, include factor V Leiden, the prothrombin gene mutation, hyperhomocysteinemia, and antiphospholipid antibodies. Thrombophilia should be suspected in patients who develop idiopathic venous thromboembolism at a young age, recurrent thrombosis, thromboses at unusual sites, recurrent unexplained pregnancy loss, or if there is a family history of thrombotic disorders. The most cost-effective approach is to initially screen for factor V Leiden, the prothrombin gene mutation, hyperhomocysteinemia, and antiphospholipid antibodies because these are the most common defects causing thrombophilia. Long-term anticoagulation is controversial but should be considered if unprovoked venous thromboembolism recurs.
静脉血栓栓塞患者中,遗传性凝血异常越来越受到关注。高凝状态(也称为易栓症)的常见原因包括因子V莱顿突变、凝血酶原基因突变、高同型半胱氨酸血症和抗磷脂抗体。对于年轻时发生特发性静脉血栓栓塞、复发性血栓形成、非寻常部位血栓形成、复发性不明原因流产或有血栓形成性疾病家族史的患者,应怀疑患有易栓症。最具成本效益的方法是首先筛查因子V莱顿突变、凝血酶原基因突变、高同型半胱氨酸血症和抗磷脂抗体,因为这些是导致易栓症的最常见缺陷。长期抗凝治疗存在争议,但如果无诱因的静脉血栓栓塞复发,则应考虑进行。